A61K 2239/13
Antibody-based
A61K2239/13 (Antibody-based) appears on 96 US grants and 735 published applications in this corpus.
Search patents in A61K- Granted patents
- 96
- Published applications
- 735
- Assignees
- 394
- Inventors
- 2,160
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 5 |
| 2017 | 0 | 4 |
| 2018 | 3 | 10 |
| 2019 | 4 | 11 |
| 2020 | 5 | 10 |
| 2021 | 3 | 18 |
| 2022 | 4 | 35 |
| 2023 | 9 | 61 |
| 2024 | 13 | 212 |
| 2025 | 27 | 226 |
| 2026 | 28 | 142 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Humanized CD19 antibody and use thereof15 Sep 2026US 12,735,482 B2Gracell Bioscience (Shanghai) Co., Ltd.
- Anti-CD20 antibodies and CAR-T structures18 Aug 2026US 12,709,644 B2TeneoBio, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
Most cited
By later US patents
- Chimeric antigen receptors targeting CD-1920US 10,287,350 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2019
- Cell19US 10,172,885 B2UCL Business PLC · 2019
- Cell13US 10,172,886 B2UCL Business PLC · 2019
- Modified NK-92 cells for treating cancer13US 10,738,279 B2NantKwest, Inc. · 2020
- Constructs targeting AFP peptide/MHC complexes and uses thereof12US 10,011,658 B2Eureka Therapeutics, Inc. · 2018